内分泌腺性血管内皮生长因子对结肠癌LoVo细胞增殖和迁移的促进作用

doi:10.13481/j.1671-587x.20180311

摘要/Abstract

摘要： 目的：探讨内分泌腺性血管内皮生长因子（EG-VEGF）对结肠癌LoVo细胞相关恶性行为的影响。方法：采用不同浓度（50、100、200μg·L^-1） EG-VEGF处理的结肠癌LoVo细胞作为EG-VEGF组，采用不含EG-VEGF培养液培养的结肠癌LoVo细胞作为对照组。MTT法检测各组LoVo细胞的增殖活性，流式细胞术（FCM）检测各细胞周期LoVo细胞百分率，细胞划痕实验检测各组结肠癌LoVo细胞迁移率，Transwell实验检测各组结肠癌LoVo细胞迁移数。结果：MTT法，与对照组比较，50、100和200μg·L^-1EG-VEGF组LoVo细胞增殖活性明显升高（P<0.05），且随着浓度的升高细胞增殖活性升高。FCM检测，与对照组比较，100μg·L^-1EG-VEGF组G₀/G₁期LoVo细胞百分率降低（P<0.05），S期细胞百分率升高（P<0.05），G₂+M期细胞百分率变化不明显。细胞划痕实验，100μg·L^-1EG-VEGF组LoVo细胞迁移率较对照组明显升高（P<0.05）。Transwell实验，50、100和200μg·L^-1EG-VEGF组结肠癌LoVo细胞迁移数较对照组明显升高（P<0.05）。结论：EG-VEGF可明显促进结肠癌LoVo细胞增殖和迁移，EG-VEGF可能与结肠癌的恶性发展有关联。

关键词: 细胞周期, 迁移, 内分泌腺性血管内皮生长因子, 结肠肿瘤, 细胞增殖

Abstract: Objective: To investigate the effect of endocrine gland-derived vascular endothelial growth factor(EG-VEGF) on the malignant behavior of colon cancer LoVo cells. Methods: The LoVo cells treated with different concentrations (50,100,and 200 μg·L^-1)of EG-VEGF were used as EG-VEGF groups,and the colon cancer LoVo cells cultured with solution without EG-VEGF were regarded as control group. The proliferation activity of LoVo cells was determined by MTT method; flow cytometry(FCM) was used to detect the percentages of LoVo cells at different cell cycles in various groups; Wound scratch assay test and Transwell cell migration assay were used to detect the migration rates of LoVo cells and the number of migration cells. Results: The MTT results showed that compared with control group,the proliferation activities of LoVo cells in 50,100,and 200 μg·L^-1EG-VEGF groups were increased significantly (P<0.05); with the increasing of concentration of EG-VEGF,the proliferation activity was increased apparently. The FCM results showed that compared with control group,the percentage of colon cancer LoVo cells at G₀/G₁ phase in 100 μg·L^-1EG-VEGF group was decreased (P<0.05) and the percentage of colon cancer LoVo cells at S phase was increased (P<0.05),but the percentage of colon cancer LoVo cells at G₂+M phase did not change significantly.The wound scratch assay results showed that compared with control group,the migration rate of LoVo cells in 100 μg·L^-1EG-VEGF group was increased (P<0.05). The Transwell assay results showed that compared with control group,the number of migration cells in 100 μg·L^-1 EG-VEGF group was increased significantly (P<0.05). Conclusion: EG-VEGF can obviously promote the proliferation and migration of colon cancer LoVo cells,and EG-VEGF may be associated with the malignant development of colon cancer.

Key words: migration, endocrine gland-derived vascular endothelial growth factor, cell cycle, cell proliferation, colon neoplasms

中图分类号:

R73-37

周刘祥, 林琳, 胡鑫敏, 王晓春. 内分泌腺性血管内皮生长因子对结肠癌LoVo细胞增殖和迁移的促进作用[J]. 吉林大学学报(医学版), 2018, 44(03): 516-520.

ZHOU Liuxiang, LIN Lin, HU Xinmin, WANG Xiaochun. Promotion effect of endocrine gland-derived vascular endothelial growth factor on proliferation and migration of colon cancer LoVo cells[J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 516-520.

参考文献

[1] Chen W,Zheng R,Zhang S,et al. Annual report on status of cancer in China,2010[J].Chin J Cancer Res,2014,26(1):48-58.
[2] 孙朝文,周崇民,张皓,等.晚期结肠癌患者生物治疗临床应用的研究进展[J].重庆医学,2017,46(8):1123-1125.
[3] LeCouter J,Kowalski J,Foster J,et al.Identification of an angiogenic mitogen selective for endocrine gland endothelium[J].Nature,2001,412(6850):877-884.
[4] Goi T,Nakazawa T,Hirono Y,et al.Prokineticin 1 expression in gastrointestinal tumors[J].Anticancer Res,2013,33(12):5311-5315.
[5] Corlan AS,Cmpean AM,Jitariu AA,et al.Endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in cancer development and tumor angiogenesis.[J].Internat J Endocrinol,2017,2017(4):3232905.
[6] Ngan ES,Tam PK.Prokineticin-signaling pathway[J].Int J Biochem Cell Biol,2008,40(9):1679-1684.
[7] 董延琥,栾文强,李兴坤,等.PROK1在结肠癌组织中的表达及其与转移的相关性[J].中国实用医药,2016,11(22):16-18.
[8] Goi T,Nakazawa T,Hirono Y,et al.The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1(No correlation coefficient between VEGF and PROK1)[J].Oncotarget,2015,6(30):28790-28799.
[9] Bai LM,Huang XF,Xu HM.Investigation of microvessel density and related factors expression for xenografts tumor of HT-29 cells in nude mice at different growth stages[J].Chin Pharmacol Bull,2014,30(6):796-800.
[10] 李西霞,王晓春.EZH2通过抑制miR-608基因表达促进结肠癌细胞增殖[J].基因组学与应用生物学,2016,35(4):745-751.
[11] Nakazawa T,Goi T,Hirono Y,et al.Prokineticin 1 protein expression is a useful new prognostic factor for human sporadic colorectal cancer[J].Ann Surg Oncol,2015,22(5):1496-1503.
[12] Traboulsi W,Bouffetal H,Aboussaouira T,et al.EG-VEGF and its receptors are deregulated in complete hydatiform moles:Potential role in placental tumor development[J].Placenta,2014,35(9):A50.
[13] Morales A,Morimoto S,Vilchis F,et al.Molecular expression of vascular endothelial growth factor,prokineticin receptor-1 and other biomarkers in infiltrating canalicular carcinoma of the breast.[J].Oncol Lett,2016,12(4):2720.
[14] Ren L,Guo X,Shao X,et al.Endocrine gland-derived vascular endothelial growth factor modulates proliferation,apoptosis and migration in pancreatic cancer cells[J].Mol Med Rep,2015,11(6):4279-4284.
[15] Goi T,Nakazawa T,Hirono Y,et al.The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer[J].Oncotarget,2015,6(8):6053-6061.
[16] Goi T,Nakazawa T,Hirono Y,et al.Anti-prokineticin1 (PROK1) monoclonal antibody suppresses angiogenesis and tumor growth in colorectal cancer[J].Ann Surg Oncol,2014,21 (Suppl 4):S665.
[17] 史剑飞,邓红玉,冯赫宇,等.靶向干扰PROK1基因对结直肠癌细胞HT29增殖和迁移的影响[J].基因组学与应用生物学,2017,36(4):1294-1300.
[18] Su MT,Tsai PY,Tsai HL,et al.miR-346 and miR-582-3p-regulated EG-VEGF expression and trophoblast invasion via matrix metalloproteinases 2 and 9[J].Biofactors,2017,43(2):210-219.
[19] Akanori G,Hidetaka K,Yuki U,et al.Expression of prokineticin-receptor2(PK-R2) is a new prognostic factor in human colorectal cancer:[J].Oncotarget,2015,6(31):31758-31766.
[20] 闻崇炜,周夕莲,刘瑞江.EG-VEGF在肿瘤治疗中的应用前景[J].中国医药导报,2010,7(1):173.
[21] 张玲,屈亚威,谈涛,等.高分辨率显微内镜对结肠癌诊断价值的初步研究[J].解放军医学杂志,2016,41(9):746-748.